awmsg logo



mercaptopurine (Xaluprine®)


Reference No. 1252

Publication date:
25/10/2012


Last review date:
30/08/2016

Appraisal information

mercaptopurine (Xaluprine®) 20 mg/ml oral suspension


Company: Nova Laboratories Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 10/07/2012
AWMSG meeting date: 12/09/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2412
Ministerial ratification: 25/10/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Mercaptopurine (Xaluprine®) 20 mg/ml oral suspension is recommended as an option for use within NHS Wales for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download